Delaware Medical Care, P.A.

Delaware Medical Care, P.A. Our mission is to provide outstanding medical care to every patient and promote good health within the community. Welcome to Delaware Medical Care, PA.

Our physician, Dr. Islam Al-Junaidi has been serving Smyrna, DE and the surrounding area for more than 15 years. We also have two Nurse Practitioners, JoAnn Baker, DNP,FNP-BC and Catherine Barber, FNP-BC on staff for your convenience. Our practice specializes in internal medicine and the treatment of adults with acute and chronic medical problems such as diabetes, hypertension, COPD, asthma, gast

rointestinal, kidney, non interventional cardiovascular, neurological disorders and other metabolic diseases. We do not treat chronic pain.

02/03/2026

A Story of Grit, Patience, and Wisdom
A true winner is not defined by speed or loud victories, but by the ability to endure when everything familiar collapses. My test of grit, patience, and wisdom began with the COVID epidemic—and nearly cost me the medical practice I had spent decades preparing to build.
I founded Delaware Medical Care on January 1, 2000, calling it a practice for the twenty‑first century. I believed we were ready for anything. For years, I had managed turbulence—regulatory pressure, staffing challenges, reimbursement cuts—and remained stable and productive. Yet when 2020 arrived, our defenses did not bend; they broke.
Patients disappeared overnight, afraid to enter the office. Revenue collapsed. Staffing became chaotic. Ironically, when some employees left, it later became clear they had been doing more harm than good. Despite having up to five practitioners, I was generating the majority of the revenue. I did not take time off for nearly five years, knowing that even a short vacation could mean failing to meet payroll or rent. The business depended on my constant presence.
From a business standpoint, this should have triggered immediate alarm. Instead, I trusted the systems and the managers I had put in place. Every concern I raised was dismissed—COVID delays, EMR transitions, billing “hiccups.” I was told everything was under control. In reality, we were barely surviving, paying bills with no real profit, drifting closer to insolvency without knowing it.
In 2022, our EMR provider of 11 years announced bankruptcy. We were forced into a rapid and expensive transition involving record archiving, billing disruption, and staff retraining. The new EMR and billing vendor turned into a financial disaster. A year later, we switched again—losing hundreds of thousands of dollars, not only from transition costs but from mismanagement and billing incompetence by people I had trusted with the financial backbone of my practice.
The most painful realization was this: the failure was not malicious—it was negligent. And ultimately, it was my responsibility. I was consumed by patient care, doing what I had been trained to do my entire life, while ignoring the uncomfortable truth that medicine is also a business. I was asleep at the wheel.
By early 2023, the consequences became undeniable. I had to borrow money from my daughter just to meet payroll. That moment—asking my child for financial help—was the lowest point of my professional life. It stripped away every illusion I had about control, success, and stability.
When I finally brought in an independent billing company, the findings were devastating. For years, we had contracted with insurance plans that either did not pay at all or reimbursed pennies on the dollar through capitation arrangements. No one had warned me. Over a decade, the cumulative loss reached millions of dollars—a slow financial bleed hidden behind false reassurance and poor oversight.
One example still makes my stomach turn. While enrolling in a Paychex 401(k) plan, I was unknowingly signed into an office HR agreement. buried inside payroll and retirement fees. I discovered this only after five years. I had never felt so foolish, violated, or betrayed. I had delegated trust without verification, and the business paid the price.
At the beginning of 2024, I made the hardest decision of my career: total corrective action. Nearly all staff were replaced. Long‑standing vendors were terminated. We transitioned to a new EMR and billing and payroll companies .
There was nothing comfortable about these decisions—but comfort was no longer the goal. Survival was.
With the strength and discipline of my wife—now serving as office manager—and a new team built on accountability, competence, and transparency, the practice began to heal. Systems stabilized. Cash flow improved. Oversight became deliberate and data‑driven.
Today, we are emerging from the abyss of near bankruptcy. For the first time in years, I took a vacation without the fear of missing payroll or rent. We are now positioned for what may be the strongest financial year in the history of the practice.
Grit kept me moving when quitting would have been easier. Patience allowed me to endure humiliation, loss, and rebuilding. Wisdom—earned the hard way—taught me that excellent medicine alone does not sustain a practice. Leadership, financial vigilance, and accountability do.
Success did not arrive as a moment of triumph. It arrived as survival, correction, and renewal. And the real winner is not the one who avoids failure—but the one who confronts it, owns it, and rebuilds stronger than before.

Call now to connect with business.

11/24/2025

This badge celebrates over 30 years of dedication to excellence and signifies a ongoing commitment to professional growth. Maintaining board certification throughout a career reflects a physician’s dedication to staying current in the knowledge, skills and attitudes essential for delivering excell...

03/09/2025
02/20/2025

Dozens of new obesity drugs are coming: these are the ones to watch
Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with fewer side effects.
For Kristian Cook, every pizza box he opened was another door closed on the path to overcoming obesity. “I had massive cravings for pizza,” he says. “That was my biggest downfall.”

At 114 kilograms and juggling a daily regimen of medications for high cholesterol, hypertension and gout, the New Zealander resolved to take action. In late 2022, at the age of 46, Cook joined a clinical trial that set out to test a combination of the weight-loss drug semaglutide — better known by its brand names, Ozempic or Wegovy — and an experimental drug designed to preserve muscle while shedding fat.

Muscle loss is a big concern for people on anti-obesity medications such as semaglutide. These ‘GLP-1 agonists’ mimic a natural gut hormone — glucagon-like peptide 1 — to suppress appetite and regulate metabolism. But reducing calories leads to an energy deficit, which the body often makes up for by burning muscle. The experimental drug that Cook received, called bimagrumab, seems to counteract this muscle loss.

Obesity drugs: huge study identifies new health risks

It’s one of more than 100 anti-obesity drug candidates that are in various stages of development. The next wave of medications, which are likely to hit pharmacy shelves in the next few years, resemble drugs that are already on the market. But close behind are numerous therapies being developed specifically for their muscle-sparing weight-loss potential. Dozens more are aimed at different biological pathways and could redefine obesity treatment in decades to come.

“We’re working to create the next generation of healthy weight-loss solutions,” says Philip Larsen, who played a key part in the early development of GLP-1 drugs and is now chief executive of SixPeaks Bio, an obesity-focused start-up company in Basel, Switzerland.

The surge in anti-obesity drug development has been made possible by the blockbuster success of semaglutide and its rival drug tirzepatide — sold as Zepbound or Mounjaro. These drugs have unlocked the potential for a global market that is projected to surpass US$100 billion by the end of the decade.

But semaglutide and tirzepatide have limitations. They require weekly injections and frequently cause unpleasant side effects, with nausea, vomiting and diarrhoea being particularly common. Long term, the loss of muscle mass and the likelihood of weight regain after stopping therapy are also issues. What’s more, the drugs don’t work sufficiently for an estimated 10–30% of people who take them.

Emerging therapies aim to amplify weight loss, improve tolerability, ensure long-lasting effects and find options for a broader range of individuals (see ‘Next up in obesity drugs’). “We’re going to see that there are different medicines that work better for different groups of people,” says Louis Aronne, an obesity specialist at Weill Cornell Medicine in New York City who consults for drug makers.

Next up in obesity drugs
Expected dates of US approval for new types of weight-loss drugs heading to market.

Estimated year

Drug

Company

Description

2026

Orforglipron

Eli Lilly

An oral, small-molecule drug that activates the glucagon-like peptide 1 (GLP-1) receptor.

2026

CagriSema

Novo Nordisk

An injectable that activates the amylin and GLP-1 receptors.

2027

Survodutide

Boehringer Ingelheim

An injectable that activates the glucagon and GLP-1 receptors.

2027

Retatrutide

Eli Lilly

An injectable that activates GLP-1, gastric inhibitory polypeptide (GIP) and glucagon receptors.

2028 and beyond

MariTide

Amgen

An injectable that activates the GLP-1 receptor while blocking GIP signalling.

2028 and beyond

Bimagrumab

Eli Lilly

An injectable that blocks receptors involved in myostatin signalling.

2028 and beyond

Monlunabant

Novo Nordisk

An oral drug that inhibits the CB1 cannabinoid receptor.

Medicare for everyone
12/10/2024

Medicare for everyone

Our health system really needs some serious overhaul
12/10/2024

Our health system really needs some serious overhaul

11/29/2024

Our nation’s ability to live healthier, longer lives rests on our commitment to supporting public health initiatives and the individuals who carry them out. CDC recognizes Public Health Thank You Day as an opportunity to express gratitude and show support to the public health workforce.

11/29/2024

PRIMARY CARE IS BECOMING UNSUSTAINABLE. SORRY, BUT IT’S TRUE.

I’ve always loved being a doctor. There’s something incredibly rewarding about the relationships I build with my patients, especially in primary care.

I get to know them over the years—hear about their lives, their families, see them through good times and bad. It’s not just about treating illnesses; it’s about being a trusted part of someone’s life.

But lately, I’ve been feeling this nagging fear creeping in.

It’s not the medicine itself that’s the issue—it’s the system.

Medicare cuts keep coming, and it feels like every year, the pressure to do more with less just keeps increasing.

The bureaucratic hoops we have to jump through are exhausting, and the compensation? It’s shrinking while our workload grows. I’m scared, honestly, about where this is heading.

I look at my schedule some days, crammed with patient after patient, and it’s not because I want to rush through visits. It’s because, financially, I don’t have a choice.

Medicare’s reimbursements have been cut so many times, and yet the cost of running a practice isn’t shrinking.

Staff salaries, overhead, supplies—it’s all going up. Meanwhile, I’m being paid less and less for the same care.

It’s unsustainable. I’m not sure how much longer we can keep this up.

I’ve been watching more and more of my colleagues move toward direct primary care (DPC) or concierge medicine.

I used to think I’d never consider it—I wanted to stay accessible to as many people as possible, to be the kind of doctor who could help everyone, regardless of their income or insurance.

But the truth is, I’m starting to see why so many are making the switch.

It’s pushing us to a breaking point, and I’m not sure how much longer I can hold out.

The passion for medicine is still there, but the reality of making it work within this system? That’s what’s making me question everything.

Every day, I try to balance the demands of my practice with the care my patients deserve, but it’s becoming harder and harder to make that balance work.

It feels like a losing battle, and I’m not alone in feeling this way. I’m just not sure how many more cuts we can take before everything starts to unravel.

And honestly? It’s terrifying.

Address

51 Deak Drive
Smyrna, DE
19977

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+13026531281

Alerts

Be the first to know and let us send you an email when Delaware Medical Care, P.A. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share